



(11) **EP 2 875 828 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
24.07.2019 Bulletin 2019/30

(45) Date of publication and mention
of the grant of the patent:
01.05.2019 Bulletin 2019/18

(21) Application number: **13766388.6**

(22) Date of filing: **19.07.2013**

(51) Int Cl.:
A61K 39/35 ^(2006.01) **A61K 39/36** ^(2006.01)
A61P 37/08 ^(2006.01)

(86) International application number:
PCT/ES2013/070527

(87) International publication number:
WO 2014/013123 (23.01.2014 Gazette 2014/04)

(54) **COMPOSITION FOR INTRADERMAL ADMINISTRATION OF ALLERGOIDS**

ZUSAMMENSETZUNG ZUR INTRADERMALEN VERABREICHUNG VON ALLERGOIDEN

COMPOSITION POUR L'ADMINISTRATION INTRADERMIQUE D'ALLERGOÏDES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **20.07.2012 ES 201231168**
08.03.2013 ES 201330335

(43) Date of publication of application:
27.05.2015 Bulletin 2015/22

(73) Proprietor: **Diater, Laboratorio de Diagnóstico y**
Aplicaciones Terapéuticas, S.A.
28918 Leganés, Madrid (ES)

(72) Inventors:
• **PALACIOS PELÁEZ, Ricardo**
28918 Leganés Madrid (ES)
• **RODRÍGUEZ GIL, David**
28918 Leganés Madrid (ES)
• **ALCOVER DÍAZ, Javier**
28918 Leganés Madrid (ES)
• **PINEDA DE LA LOSA, Fernando**
28918 Leganés Madrid (ES)

(74) Representative: **ABG Intellectual Property, S.L.**
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid (ES)

(56) References cited:
EP-A1- 0 782 860 WO-A1-2011/026641
WO-A1-2011/098569 GB-A- 1 282 163
US-A- 4 180 562 US-A- 4 269 764
US-A- 4 473 495

- **MALET A ET AL: "Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract", ALLERGOLOGIA ET IMMUNOPATHOLOGIA, GARSÍ, MADRID, ES, vol. 22, no. 5, 1 September 1994 (1994-09-01), pages 226-232, XP008098988, ISSN: 0301-0546**
- **ARTS JOSJE H E ET AL: "Dose-response relationships and threshold levels in skin and respiratory allergy", CRITICAL REVIEWS IN TOXICOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 36, no. 3, 1 March 2006 (2006-03-01), pages 219-251, XP008166098, ISSN: 1040-8444, DOI: 10.1080/10408440500534149**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).